© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
The American Society of Hematology Annual Meeting, 2014
Bigger Regulatory Challenges in Diagnostics Than in Therapeutics, Industry Expert Says
January 20, 2015
Article
Evidence-Based Oncology
Data Show High Response Rate to Ibrutinib Combination for Patients With Hard-to-Treat MCL
January 20, 2015
Article
Evidence-Based Oncology
Best of ASH Presentations: Platelets, Lenalidomide for MDS, and Sorafenib in AML
January 20, 2015
Article
Evidence-Based Oncology
Results Project Savings for Payers With Novel Oral Anticoagulants
January 19, 2015
Article
Evidence-Based Oncology
SPIRIT 2: Dasatinib Superior to Imatinib in Newly Diagnosed CML
January 19, 2015
Article
Evidence-Based Oncology
CML Updates: Defining MMR and Results of the DASISION Trial
January 19, 2015
Article
Evidence-Based Oncology
Sessions Report Phase 2 Results of Pomalidomide Combinations
January 19, 2015
Article
Evidence-Based Oncology
Promising Results for Elotuzumab Presented in Session on Multiple Myeloma
January 19, 2015
Article
Evidence-Based Oncology
Early Treatment, Monoclonal Antibodies Discussed in Multiple Myeloma
January 19, 2015
Article
Evidence-Based Oncology
ASH Presents Second Round of Tests, Treatments to Question Under Choosing Wisely Initiative
January 19, 2015
Article
Evidence-Based Oncology
Care Plans to Reduce Healthcare Utilization in Sickle Cell Disease
January 19, 2015
Article
Evidence-Based Oncology
Healthcare Costs in Need of Solutions: Experts at ASH Agree
January 19, 2015
Article
Evidence-Based Oncology
Session on Survivorship Outlines Surveillance Strategies in Non-Hodgkin Lymphoma
January 19, 2015
Article
Evidence-Based Oncology
Ibrutinib Demonstrates Significant Responses for Patients With Hard-to-Treat CLL/SLL, Phase 2 Data Show
January 19, 2015
Article
Evidence-Based Oncology
Study Suggests Method of Reducing Blood Clots Without Risking Bleeding
January 19, 2015
Article
Evidence-Based Oncology